The results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study show that administering the low molecular weight heparin (LMWH) enoxaparin sodium in combination with glycoprotein (GP) IIb/IIIa receptor antagonists to patients receiving treatment for acute coronary syndromes does not result in any more bleeding problems than would be expected using unfractionated heparin. The results of NICE-3 were presented at the 22nd Congress of the European Society of Cardiology [Amsterdam, The Netherlands; August 2000].